Limb girdle muscular dystrophy (LGMD) describes a group of inherited diseases resulting from mutations in genes encoding proteins involved in maintaining skeletal muscle membrane stability.
LGMD type-2D is caused by mutations in alpha-sarcoglycan (sgca). Here we describe muscle-specific gene delivery of the human sgca gene into dystrophic muscle using an adeno-associated virus 1 (AAV1) capsid and creatine kinase promoter. Delivery of this construct to adult sgca −/− mice resulted in localization of the sarcoglycan complex to the sarcolemma and a reduction in muscle fiber damage. Sgca expression prevented disease progression as observed in vivo by T 2 -weighted magnetic resonance imaging (MRI) and confirmed in vitro by decreased Evan's blue dye accumulation. The ability of recombinant AAV-mediated gene delivery to restore normal muscle mechanical properties in sgca −/− mice was verified by in vitro force mechanics on isolated extensor digitorum longus (EDL) muscles, with a decrease in passive resistance to stretch as compared with untreated controls. In summary, AAV/AAV-sgca gene transfer provides long-term muscle protection from LGMD and can be non-invasively evaluated using magnetic resonance imaging.
IntroductIon
The limb girdle muscular dystrophies (LGMDs) are a group of inherited syndromes characterized by progressive muscle wasting as a result of the breakdown of muscle fiber membrane integrity. Some of these are caused by autosomal dominant mutations, but many forms of LGMD are autosomal recessive disorders caused by mutations in a gene encoding one of the sarcoglycan proteins. The sarcoglycans comprise a complex that consists of a combination of up to six glycosylated transmembrane proteins. 1 This sarcoglycan complex is a small but integral portion of the large dystrophin glycoprotein complex that is vital for maintaining muscle fiber integrity.
The standard care for patients suffering from LGMD-2D is currently aimed at delaying disease progression through lowstress activities; no true treatment is available. For this reason, and because LGMD-2D is the result of a single gene defect, the development of a clinically applicable gene delivery technique combined with non-invasive assessment methods is highly desirable.
Using either adenovirus or the adeno-associated virus (rAAV) gene delivery systems, investigators have demonstrated that providing a correctly functioning form of the sgca gene to muscle tissue in a knockout mouse is sufficient to re-establish the dystrophin glycoprotein complex connection to muscle fiber membranes and protect tissue from damage. [2] [3] [4] Experiments using adenovirus to deliver the sgca gene have demonstrated at least 90% transduction of muscle fibers and an overall decrease in dystrophic lesion formation after a single intra-muscular (IM) injection into neonates. 2 These studies were important for proving the concept that gene delivery is a potential treatment option for this disease.
rAAV has emerged as a strong candidate for skeletal muscle gene transfer because of its ability to infect non-dividing cells, its ability to persist for long periods, and its proven safety in vivo. [5] [6] [7] [8] [9] [10] It has been shown that delivery of the sgca gene using rAAV serotype 2 (rAAV2) results in alpha-sarcoglycan expression and successful localization of the entire sarcoglycan complex to the myofiber membranes. 3 It was observed that between 28 and 41 days after injection a dramatic decrease in sgca expression occurred in these muscles. Further analysis indicated that this was believed to be the result of sgca over-expression using a CMV promoter. 3 These studies revealed that a fine balance exists in the protein expression within myofibers, which must be maintained to achieve functionally corrective expression levels of alpha-sarcoglycan and concurrently avoid the elicitation of an immune response and subsequent negative consequences. Here we describe a series of experiments that have achieved this balance through the use of a construct that exploits the rAAV1 capsid in combination with a truncated creatine kinase-based muscle-specific promoter to achieve a physiologically more accurate level of sgca expression.
We hypothesized that the use of an rAAV1/2 pseudotype containing a truncated creatine kinase promoter would result in early muscle-specific expression of human sgca, achieving sufficient amounts of sgca protein to maintain cell membrane integrity without eliciting an immune response. Furthermore, the effect of sgca expression on function and morphology would be corrective and prevent disease progression in both adult and newborn sgca −/− mice. To test this hypothesis, functional correction was determined using in vitro force mechanics and histological analysis was performed on tissue sections. In addition, magnetic resonance imaging (MRI) was used to monitor dystrophic lesion development over time non-invasively. In lieu of human clinical trials for this therapy, there is a great need for a non-invasive, quantitative assessment technique to establish efficacy.
results

In vitro sgca gene expression
Infection of differentiated primary sgca −/− myotubes with the rAAV2/1-tMCK-sgca viral construct results in the expression of sgca. Myoblasts were isolated from sgca −/− neonates and forced into differentiation using previously described methods. 11 Once fully differentiated, the sgca −/− myotubes were infected with rAAV2/1-tMCK-sgca at an multiplicity of infection of 10,000 (Figure 1a ). An anti-desmin antibody was used to show myoblast differentiation (red), and sgca protein (green) was detected after infection by immunofluorescence and by western blot analysis (data not shown).
Sgca gene delivery to adult sgca −/− mice Histopathological signs associated with LGMD were reduced 2 months after IM injection of 1 × 10 11 vector genomes (vg) of rAAV2/1-tMCK-sgca in adult sgca −/− tibialis anterior and extensor digitorum longus (EDL) muscles. In vitro tissue analysis revealed that treated legs displayed numerous sgca + muscle fibers and improved morphology compared with untreated contra-lateral hindlimb muscles in terms of both decreased membrane permeability [determined by the number of Evans blue dye (EBD)-positive fibers] and decreased fibrosis in areas expressing sgca (Figure 1b; upper panels) .
A second cohort of animals showed continued tissue correction 6 months after vector administration. Immunofluorescence analysis revealed that only those muscles injected with the rAAV2/1-tMCK-sgca construct expressed sgca, and those located in the uninjected contra-lateral hindlimb displayed a notable increase in the number of EBD-positive muscle fibers and areas with fibrosis (Figure 1b ; lower panels).
Functional correction in sgca −/− mice treated as adults A passive resistance to stretch protocol was performed on EDL muscles from both treated and untreated hindlimbs of sgca −/− mice at 6 months after injection. rAAV2/1-tMCK-sgca-injected muscles were found to have a resistance to passive stretch of 5.24 ± 2.12 g/cm 2 and were similar to healthy age-matched B6/129 EDL muscles (8.53 ± 0.67 g/cm 2 ; P-value = 0.32; Figure 2 ). Untreated sgca −/− EDL muscles fell into two distinct categories: those generating an abnormally low resistance to passive stretch (1.56 ± 0.29 g/cm 2 ; P-value = 0.0001) and those demonstrating an abnormally high resistance to passive stretch (17.03 ± 2.59 g/cm 2 ; P-value = 0.04) compared with age-matched controls. A relationship between high resistance to stretch and fibrosis was observed in one group (fibrotic lesions), and the second group displayed a correlation between low resistance to passive stretch and the number of EBD-positive fibers (EBD lesions). Analysis of tissue sections by blinded observers revealed that on average 66% of all EDL fibers were expressing the sgca gene in treated muscles. Low levels of EBD infiltration and no fibrosis were observed in cryosections of sgca-expressing muscles at either 2 or 6 months after vector administration.
IM delivery to newborn sgca −/− mice We determined the effect of rAAV2/1-tMCK-sgca administered before the onset of lesion development using a method that achieves wide vector distribution and its effect on the formation of dystrophic lesions. One-day-old sgca −/− neonates (n = 6) were injected with 1 × 10 11 vg of rAAV2/1-tMCK-sgca in one hindlimb (IM, total volume 35 μl) and 1 × 10 11 vg of rAAV2/1-tMCK-LacZ in the contra-lateral hindlimb (single injection per leg). The contralateral mock injections were necessary to control for the potential effect of muscle repair mechanisms being triggered through the physical act of needle administration into muscle. We observed no such corrective or damage-preventing affect when the rAAV2/1-tMCK-LacZ-injected sgca −/− muscles were compared with uninjected, untreated sgca −/− muscles.
MrI technique for assessing damaged muscle tissue
Areas of muscle damage were determined non-invasively using MRI. The hindlimbs of injected mice were imaged using a single tuned solenoid coil and T 2 -weighted MRI beginning at 4 weeks of age (4 weeks after injection). Twelve diffusion-controlled T 2 -weighted images were acquired (from ankle to knee) to calculate the total damaged area in each hindlimb (Figure 3) . 12, 13 The image pixels with an elevated T 2 non-invasively identified the volume of dystrophic lesion development in each hindlimb over 3-week intervals throughout the course of the experiment (Figure 3a and b). The two-dimensional images displayed correspond to the maximal cross-sectional area of the lower hindlimb (slice 9 or 10 from sets of 12 images beginning at the ankle and ending at the knee). When considered as a group, the affected tissue volumes within the untreated hindlimbs were significantly (P-value ≤ 0.001) higher than those observed within either rAAV2/1-tMCKsgca-treated hindlimbs or healthy age-matched controls that © The American Society of Gene Therapy showed similar results throughout the duration of this experiment (Figure 3c ). The relatively small number of elevated voxels detected in healthy hindlimbs are indicative of partial volume effects from subcutaneous fat. A three-dimensional rendering of pixels with elevated T 2 (shown in red in Figure 3d ) based on the multi-slice T 2 images of both mouse hindlimbs (in blue) is shown in Figure 3d and demonstrates the extent of lesion development throughout the muscles of the right lower hindlimb and the lack of damage in the left (treated) lower hindlimb (Figure 3d) . sgca expression and tissue analysis of newborn treated mice EBD analysis [both bright-field (blue) and epifluorescence (red)] of excised whole muscles from these mice clearly confirmed what was observed using the MRI T 2 technique: muscles from untreated hindlimbs accumulated EBD and muscles from the treated contralateral hindlimbs did not (Figure 4a and b) (n = 6). Cryosection analysis showed that all muscles from the hindlimbs injected with the rAAV2/1-tMCK-sgca construct were expressing sgca and those muscles from the contra-lateral hindlimbs had no expressions (Figure 4f and i) . On average, 79% of treated EDL muscle fibers displayed sgca expression. The control injected hindlimbs displayed widespread expression of LacZ in some areas (data not shown), whereas other areas, which corresponded to fibrosis, completely lacked expression. This lack of expression is most likely due to loss of vector-containing muscle fibers as a result of lesion formation and subsequent cell degradation.
Serial sections from these muscles were also stained for the gamma-sarcoglycan (sgcg) protein (Figure 4d, g, and j) . As expected, sgcg was observed only in those fibers in which the sgca protein was present. This indicated that in the presence of sgca, other components of the sarcoglycan complex were able to migrate to their normal position at the sarcolemma. We did not observe EBD infiltration in areas where sgca protein was present, suggesting that a fully functional dystrophin glycoprotein complex in the membrane was providing those muscle fibers protection from lesion development.
Passive stretch analysis of neonatally treated mice
Neonatally treated muscles developed neither the tendency to display an abnormally low resistance to passive stretch (indicative of early-stage lesion development; 3.15 ± 0.38 g/cm 2 ) nor the abnormally high resistance to passive stretch (indicative of latestage lesion development; 17.46 ± 1.02 g/cm 2 ) that was observed in age-matched, untreated, or mock-injected control EDL muscles (Figure 4l) . The resistance to stretch of healthy age-matched (4-month-old) wild-type control muscles was 8.53 ± 0.34 g/cm 2 and that of rAAV2/1-tMCK-sgca-treated muscles was similar at 7.00 ± 0.61 g/cm 2 (n = 6); these results were significantly different from those for untreated fibrotic muscles (P-value = 0.007). This demonstrated that early treatment not only preserves muscle fiber integrity, as demonstrated by MRI and EBD analysis, but also provides preservation of mechanical function in those muscles expressing sgca.
long-term expressions 1 year after neonatal administration
Longevity of expression and subsequent prevention of the disease phenotype was evident out to 1 year after administration of rAAV2/1-tMCK-sgca. One-day-old sgca −/− neonates (n = 4) were injected with 1 × 10 11 vg of rAAV2/1-tMCK-sgca in one hindlimb (IM, total volume 35 µl) and 1 × 10 11 vg of rAAV2/1-tMCK-LacZ in the contra-lateral hindlimb (single injection per leg). Tissues were harvested 1 year after injection. Analysis of excised muscles using bright field and epifluorescence demonstrated little to no EBD uptake in treated legs as compared with LacZ-injected controls (Figure 5a and b) . Tension generation during a passive stretch showed a significant difference (P-value = 0.032) between the resistance to stretch displayed by treated EDL muscles and that displayed by untreated controls, with untreated muscles showing a resistance threefold greater than that observed in age-matched, healthy B6/129 EDL muscles (Figure 5c ). At this 1-year time point all untreated sgca −/− muscles had an increased resistance to stretch, indicative of these tissues undergoing late-stage lesion development and fibrosis. Histological analysis of cryosections d, g, j) , and dystrophin (e, h, k). (l) Passive stretch force mechanics on EDL muscles from mice injected with rAAV2/1-tMCK-sgca, wild-type controls, and uninjected sgca −/− mice (n = 6 per group) at 3 months of age (3 months after injection). Arrows point to an example of a treated EDL and an EBD-infiltrated untreated EDL. Resistance to stretch of treated sgca −/− EDL muscles is comparable to that of healthy age-matched wild-type controls. All EDL muscles from rAAV2/1-tMCK-sgca-treated legs demonstrated the presence of sgca protein by immunohistological staining in at least 50% of myofibers.
showed that on average 73% of EDL muscle fibers from rAAV2/1-tMCK-sgca hindlimbs displayed sgca protein expression 1-year after administration (Figure 5d ). Antibody staining of cryosections also identified sgca expression in the gastroc and tibialis anterior muscles of treated hindlimbs but not in the contra-lateral hindlimbs (Figure 5f-i) .
Another hallmark of dystrophic muscle fibers is their tendency to display centralized nuclei. The presence of centralized nuclei is often associated with muscle fiber regeneration, along with fiber size variations, fiber necrosis, and fiber atrophy 14 and has been previously described in this model. 15 In the current studies we did not observe the reversal of this phenotype when rAAV2/1-tMCK-sgca was administered to adult sgca −/− mice. On the other hand, histological analysis of muscles injected at 1 day of age showed that we did successfully prevent this from occurring in those muscles treated before the onset of lesion development. Blinded analysis of EDL muscle sections from six treated and six untreated hindlimbs at 1 year after rAAV2/1-tMCK-sgca administration revealed that 2% of the muscle fibers expressing sgca displayed centralized nuclei, whereas 100% of fibers not expressing sgca displayed centralized nuclei.
Finally, we performed a caspase 3 stain on cryosections from muscles of treated and mock-injected hindlimbs. Analysis of tissue sections from our experiments showed that caspase 3 was apparent only in areas of extremely late-stage lesion development where fibrosis and deterioration of muscle fibers had previously occurred; it was not found in treated muscles (Figure 5j-m) .
dIscussIon
The overall aim of this study was to determine whether disease progression can be prevented in a mouse model of LGMD-2D using an AAV-mediated gene delivery technique. We found that the expression of sgca prevented disease progression, as observed in vivo by MRI T 2 assays and three-dimensional image reconstruction. This outcome was confirmed in vitro by a decrease in Evan's blue dye accumulation, trichrome staining, and immunohistochemistry. The ability of rAAV2/1-mediated gene delivery to restore normal mechanical properties in sgca −/− mice was verified by in vitro force mechanics on isolated EDL muscles. Moreover, we found that the use of a muscle-specific promoter and the AAV2/1-pseudotyped vector provides long-term expression of sgca and results in protection of skeletal muscle integrity in sgca −/− mice for up to at least 1 year after vector administration. This lends further support to a recent study by Fougerousse et al. that demonstrated similar success using an intra-arterial delivery method. 16 The expression of sgca lasts for up to 6 months after injection following delivery of our rAAV2/1-tMCK-sgca construct to adult sgca −/− mice and up to at least 1 year following a single IM injection in 1-day-old neonates. Although some amount of disease correction following adult administration was observed, prevention of the typical disease phenotypes (lesion development, resistance to stretch, and tissue fibrosis) was achieved following vector administration at the earlier, 1-day-old time point.
In measuring the resistance to stretch of treated and untreated sgca −/− muscles and comparing them to results for age-matched wild-type controls, we found that whereas early treatment resulted in correction of this phenotype to wild-type levels, treatment in adult muscle tissue attenuated the phenotype to approximately 50% wild-type values. Our histological analyses of gene delivery to neonatal and adult tissues suggest that there is a window of opportunity during disease progression when a muscle fiber can still be protected. Beyond this point the muscle has progressed too far down the cascade of tissue damage for recovery or even the ability to halt further damage.
Our observation that the passive stretch performance of EDL muscles from untreated sgca −/− animals fell into two categories early on-high and low (resistance to stretch), corresponding to EBD lesion formation and fibrosis (respectively)-and only one category by a year of age-high resistance to stretch-suggests a model for the progression of muscle wasting and fibrosis in this disease. The early-stage lesions (deemed so by EBD infiltration and/or MRI T 2 assessment) are indicative of decreased sarcolemmal integrity. These fragile membranes operating with inadequate dystrophin-glycoprotein complexes are then unable to perform their proper force modulation functions, including providing stretch resistance. On the basis of our findings, once the myofiber reaches this state it is destined to proceed down a pathway of destruction that includes collagen infiltration and fibrosis in the later stages. The passive stretch data reported here demonstrate the relative inflexibility of EDL muscles comprised of collagenous fibers as compared with the healthy normal or treated EDL muscles in which membrane stability was maintained.
One of the many difficulties in designing a therapeutic approach to a disorder such as LGMD-2D is the progressive nature of these types of diseases. It would therefore be ideal to initiate gene delivery immediately upon diagnosis in the clinical setting to halt further disease progression and maintain an overall higher quality of life for patients.
An additional challenge to designing a gene delivery approach for the dystrophies is that many of the affected proteins are membrane bound and not secreted. When delivering genes encoding secreted proteins, one has the potential advantage of using the injected muscle as a depot or factory for producing sufficient amounts of protein to be secreted and distributed throughout the entire body. 17 Because the sgca protein is not secreted, the viral gene delivery vehicle must transduce each individual fiber in which expression is desired for that muscle cell to display the protein. Our passive stretch analyses indicates that transduction of at least 50% of muscle fibers in the EDL was sufficient to provide protection of that particular muscle from the typical resistance to stretch that develops as dystrophic lesions progress from "leaky" muscle fibers into areas of fibrotic collagen. This confirms that complete transduction of every cell in a tissue is not required for successful protection of skeletal muscle.
Caspase 3 is one of many proteases that mediate the execution of apoptosis, or the intrinsic suicide mechanism by which cells destroy themselves. Stained tissue sections showed caspase 3 expression in only a few areas of severe fibrosis in muscles from untreated hindlimbs; it was not observed in any of the treated muscles.
We chose to perform MRI assessment for detection of areas of damaged tissue (dystrophic lesion development) at 3-week intervals beginning at 4 weeks of age and ending at 13 weeks of age. Tissue section analysis in a preliminary experiment showed that no EBD uptake occurs until this time point. This is therefore a critical developmental window when the onset of dystrophic lesion growth occurs owing to muscle damage and MRI can be most easily used to detect these areas owing to shifts in water compartmentalization. Fibrosis progresses as the mouse ages, and the infiltration of collagen into damaged areas may reduce the ability of this particular MRI technique to identify those late-stage fibrotic lesions owing to the ultrashort T 2 associated with collagen. Other MRI techniques that rely on magnetization transfer or differences in apparent diffusion of water and metabolites may provide additional information in fibrotic tissues to complement the T 2 measurement.
In comparison to extraction of muscle biopsies, the use of MRI for non-invasive analysis of skeletal muscle integrity is an attractive method for assessing the success of any therapy aimed at preventing the progression of muscular dystrophy. Here we implement a recently developed T 2 mapping method to identify areas of tissue damage as a result of dystrophic lesion development within skeletal muscle. This technique can be easily applied to humans and used for analysis of other muscular dystrophies or diseases in which the integrity of muscle fiber membranes is compromised, allowing for excess water, albumin, or serum proteins to occur. Importantly, to differentiate between muscles that were corrected after AAV delivery of scga and those in which the disease was allowed to progress, the injection of a contrast reagent was not required. These studies clearly demonstrate the ability of this method to provide in vivo monitoring of the beneficial effects of therapeutic vector delivery to sgca −/− knockout muscle tissue.
In conclusion, we have developed an AAV2/1-mediated gene delivery system that demonstrates successful prevention of the LGMD-2D phenotype when delivered at an early age in a mouse model of the disease. This construct is also able to protect adult tissue from further damage when delivered at a later time point. In addition, we have demonstrated the application of a non-invasive, MRI-based T 2 mapping technique to monitor the development of dystrophic lesions over time (or lack thereof) in vivo. The results of these studies indicate that further investigation of these techniques is warranted in human patients suffering from LGMD-2D. 1-2 l) . One-dayold sgca −/− mice were anesthetized by induced hypothermia. For adults, the area of the lower hindlimb was cleaned and depilatory cream was used to remove fur. A 29.5-G tuberculin syringe was used to perform single IM injections of each vector diluted in phosphate-buffered saline (total volume of 35 µl per injection) into 1-day-old neonate and adult legs. The needle point was inserted near the bundle of tendons at the ankle and pointing up into the tibialis anterior along the tibia to the knee for adult hindlimbs and into quadriceps area for neonate injections. For both adult and 1-day-old neonate injections the virus solution was injected while withdrawing the needle to maximize volume distribution.
Non-invasive MRI T 2 assessment. MRI experiments were performed as previously described. 12, 13 In brief, each mouse was sedated with a mixture of 1.5% isofluorane and O 2 (1-2 l) (n = 6 per group, per time point). The lower hindlimbs were aligned next to one another, positioned inside a five-turn, 1.5-cm inner diameter, single-tuned proton solenoid coil, and MR imaged using a 4.7-tesla Bruker Avance spectrometer. After an initial positioning scan, multiple-slice, diffusion controlled, single spin-echo images were acquired with the following parameters: pulse repetition time, 2,000 ms; echo times, 14 and 40 ms; field of view, 10-20 mm; slice thickness, 0.5-1.0 mm; acquisition matrix size, 256 × 128; diffusion weighting, 3 mm 2 /s, and two signal averages. To avoid the contribution of stimulated echoes to the T 2 measurement, we implemented a Hahn spin-echo MR image sequence in which two separate acquisitions were acquired at echo times of 14 and 40 ms. T 2 maps and volumes of elevated T 2 s were determined using custom software (Interactive Data Language; ITT Industries, Boulder, Co; RSI, Boulder, CO). Three-dimensional data were rendered using Osirix Dicom viewing software (http://homepage.mac.com/rossetantoine/osirix/). Statistics were calculated using a Student's t-test.
Force mechanics. All resistance to force mechanics measurements were performed in vitro as previously described. [22] [23] [24] In brief, EDL muscles were tied to a force transducer at full length (L 0 ). Each muscle was extended to 110% L 0 then allowed to relax, and resistance to stretch was measured. The passive stretch experiment was performed three times per muscle and resistances were averaged. Statistics were calculated using a Student's t-test.
